Cantor Fitzgerald Reiterates $10.00 Price Target for Amarin (NASDAQ:AMRN)

Cantor Fitzgerald set a $10.00 price objective on Amarin (NASDAQ:AMRN) in a report issued on Friday, February 16th. The firm currently has a buy rating on the biopharmaceutical company’s stock.

Other equities research analysts have also issued research reports about the company. HC Wainwright reiterated a buy rating and issued a $10.00 target price on shares of Amarin in a research report on Thursday, November 2nd. BidaskClub raised Amarin from a hold rating to a buy rating in a report on Friday, December 29th. ValuEngine raised Amarin from a sell rating to a hold rating in a report on Saturday, November 4th. Finally, Zacks Investment Research downgraded Amarin from a buy rating to a hold rating in a report on Friday, November 3rd. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and three have given a buy rating to the company’s stock. Amarin currently has an average rating of Hold and an average target price of $7.75.

Shares of Amarin (AMRN) traded up $0.03 during midday trading on Friday, reaching $3.70. The company had a trading volume of 898,327 shares, compared to its average volume of 2,550,000. The stock has a market capitalization of $1,010.00, a price-to-earnings ratio of -13.70 and a beta of 0.50. Amarin has a 52-week low of $2.85 and a 52-week high of $4.60. The company has a current ratio of 1.63, a quick ratio of 1.32 and a debt-to-equity ratio of -1.48.

In other Amarin news, insider Steven B. Ketchum sold 128,257 shares of the company’s stock in a transaction on Tuesday, January 2nd. The stock was sold at an average price of $4.25, for a total value of $545,092.25. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider John F. Thero bought 10,000 shares of the company’s stock in a transaction on Thursday, November 30th. The stock was bought at an average price of $3.24 per share, with a total value of $32,400.00. The disclosure for this purchase can be found here. Over the last three months, insiders sold 426,720 shares of company stock valued at $1,814,296. 3.72% of the stock is owned by corporate insiders.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in AMRN. Paloma Partners Management Co purchased a new position in shares of Amarin during the 4th quarter worth $141,000. Hoylecohen LLC purchased a new position in shares of Amarin during the 4th quarter worth $142,000. Wells Fargo & Company MN grew its holdings in shares of Amarin by 15.2% during the 2nd quarter. Wells Fargo & Company MN now owns 37,801 shares of the biopharmaceutical company’s stock worth $152,000 after purchasing an additional 5,000 shares during the period. Cubist Systematic Strategies LLC purchased a new position in shares of Amarin during the 3rd quarter worth $226,000. Finally, Stevens Capital Management LP purchased a new position in shares of Amarin during the 3rd quarter worth $229,000. Institutional investors and hedge funds own 37.28% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This piece was originally reported by The Lincolnian Online and is owned by of The Lincolnian Online. If you are viewing this piece on another website, it was illegally stolen and republished in violation of United States and international copyright and trademark law. The legal version of this piece can be accessed at https://www.thelincolnianonline.com/2018/02/24/amarin-amrn-given-a-10-00-price-target-at-cantor-fitzgerald.html.

About Amarin

Amarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company operates through the development and commercialization of Vascepa segment. The Company’s lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia.

Receive News & Ratings for Amarin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply